FDA Approval of Eteplirsen for Muscular Dystrophy

Affiliations

Comment

Stanley F Nelson et al. JAMA. 2017.

. 2017 Apr 11;317(14):1480.

doi: 10.1001/jama.2017.2601.

¹ Center for Duchenne Muscular Dystrophy, David Geffen School of Medicine at University of California, Los Angeles.

No abstract available

Comment in

FDA Approval of Eteplirsen for Muscular Dystrophy-Reply.
Kesselheim AS, Avorn J. Kesselheim AS, et al. JAMA. 2017 Apr 11;317(14):1481-1482. doi: 10.1001/jama.2017.2605. JAMA. 2017. PMID: 28399248 No abstract available.

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.
Kesselheim AS, Avorn J. Kesselheim AS, et al. JAMA. 2016 Dec 13;316(22):2357-2358. doi: 10.1001/jama.2016.16437. JAMA. 2016. PMID: 27775756 No abstract available.